Laron syndrome historical perspective

Jump to: navigation, search

Laron syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Laron Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Laron syndrome historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Laron syndrome historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Laron syndrome historical perspective

CDC on Laron syndrome historical perspective

Laron syndrome historical perspective in the news

Blogs on Laron syndrome historical perspective

Directions to Hospitals Treating Laron syndrome

Risk calculators and risk factors for Laron syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical perspective

It is named after Zvi Laron, the Israeli researcher who, with A. Pertzelan and S. Mannheimer, first reported the condition in 1966[1][2], based upon observations which began in 1958.[3]

Resistance to GH was first reported by Laron in 1966. Since then, severe resistance to GH, characterized by grossly impaired growth despite normal levels of GH in serum, has been termed Laron syndrome.

Homo floresiensis

Recent publications have proposed that Homo floresiensis represented a population with widespread Laron syndrome.[4][5]

References

  1. synd/2825 at Who Named It
  2. Laron Z, Pertzelan A, Mannheimer S (1966). "Genetic pituitary dwarfism with high serum concentation of growth hormone--a new inborn error of metabolism?". Isr. J. Med. Sci. 2 (2): 152–5. PMID 5916640.
  3. Laron Z (2004). "Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003". J. Clin. Endocrinol. Metab. 89 (3): 1031–44. PMID 15001582.
  4. Hershkovitz I, Kornreich L, Laron Z (2007). "Comparative skeletal features between Homo floresiensis and patients with primary growth hormone insensitivity (Laron syndrome)". Am. J. Phys. Anthropol. 134 (2): 198–208. doi:10.1002/ajpa.20655. PMID 17596857.
  5. Culotta E (2007). "Paleoanthropology. The fellowship of the hobbit". Science. 317 (5839): 740–2. doi:10.1126/science.317.5839.740. PMID 17690271.

Linked-in.jpg